Clovis Oncology's Sales Growth Slows in Q4
Clovis Oncology (NASDAQ: CLVS) closed out last year with fourth-quarter sales of its cancer drug Rubraca up 30% year over year to $39.3 million. The figure was at the high end of the preliminary sales estimate the company announced in January, but it still represents a slowdown in growth for the entire year when sales increased 50% year over year.
The biotech gave away $8 million worth of the drug, which was 18% of the commercial supply. While still a substantial amount, Clovis has improved coverage of the drug by payers; this time last year, the supply of free drug was 26% of the commercial supply.
Image source: Getty Images.
Source Fool.com
